A market value of roughly US$ 1.7 Bn for Anti-Psychotics drugs is estimated in 2017 and this will increase to about US$ 5.6 Bn by the end of 2025.

Albany, New York, October 6, 2017: The global orally disintegrating tablets market is likely to reach revenues to the tune of US$ 27 bn by the end of 2025, according to a new research added to the database of repository of Market Research Reports Search Engine (MRRSE). According to the report, global orally disintegrating tablets market is projected to grow at a CAGR of over 11% throughout the forecast period. The report titled “Orally Disintegrating Tablets Market: Global Industry Analysis 2012 – 2016 and Forecast 2017 – 2025” offers comprehensive information on the prospects of the global market during the forecast period 2017-2025.

Request Free Sample Report: https://www.mrrse.com/sample/3422

As per the report, the demand for tablets that disintegrate globally is largely fuelled by advances in drug innovation and government support. Pharmaceutical companies are making the shift from solid dosage to orally disintegrating tables as the latter offer benefits in terms of administration. Further, innovation in drug formulation has enabled pharmaceutical companies to launch these drugs in novel forms, thereby increasing their reach.

The report on global orally disintegrating tablets market has segmented the global market on the parameter of drug class, distribution channel, disease indication, and region. On the basis of drug class segmentation, the anti-psychotics segment remains the most lucrative, and is likely to account for a revenue share of nearly 20% by the end of 2025. In terms of revenues, this will represent revenues worth US$ 5.6 in 2025, up from US$ 1.7 bn in 2017. The second-most lucrative segment by product type is anti-epileptics drug. By 2025, this segment is likely to hold a revenue share of nearly 13%.

By disease indication, CNS disease segment is likely to account for a leading share of the market. According to the report, the CNS disease segment is likely to grow at over 13% CAGR during the forecast period 2017-2025, and reach a valuation of nearly US$ 15 bn. In terms of revenues, this will represent a revenue share of nearly 55%.

Browse Full Report with TOC: https://www.mrrse.com/orally-disintegrating-tablet-market

Amongst the numerous distribution channels, hospital pharmacies are expected to account for a sizeable revenue share. The report projects global revenues to grow at over 13% CAGR during the forecast period and reach US$ 13 bn by 2025.

North America is the largest market for orally disintegrating tablets, and will remain an attractive market throughout the forecast period. According to the report, the market in North America is likely to grow at nearly 12% CAGR and reach US$ 10 bn in revenues.

The leading players in the market include Novartis AG, Teva Pharmaceutical Industries Ltd., Hoffmann-La Roche Ltd., Valeant, Eisai Co., Ltd., Glenmark, NEOS Therapeutics, Inc., Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., BJohnson & Johnson Services, Inc., Mylan N.V., AstraZeneca, Pfizer Inc., F. Merck & Co., Inc., GlaxoSmithKline plc., Bayer AG, Zydus Cadila, and Unichem Laboratories.

Enquire About this Report: https://www.mrrse.com/enquiry/3422

Contact Details

Keywords : Orally Disintegrating Tablets Market, Orally Disintegrating Tablets Market Report, Orally Disintegrating Tablets Market Analysis, Orally Disintegrating Tablets Market Growth, Orally Disintegrating Tablets Market Forecast,

by ARSLAN (last year!)